Dr Lonial, presenting at the IV International Workshop on Myeloma Genetics, Pharmacogenomics & Novel Therapeutics, talks about novel clinical trials designs particularly for melanoma. He discusses the importance of trial designs which give patients faster and less toxic doses of treatment.

The workshop was supported by an unrestricted medical education grant from the following companies; Celgene, Bristol Myers Squibb, Johnson and Johnson, Takeda Millennium, Novartis Oncology, Cephalon and Onyx Pharmaceuticals.